<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app23.us.archive.org';v.server_ms=528;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml', '20180712200843')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20180712200843/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20180712200843/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20180712200843" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610080231/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml" title="10 Jun 2018"><strong>Jun</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 20:08:43 Jul 12, 2018">JUL</td>
		  <td class="f" nowrap="nowrap">Aug</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610080231/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml" title="08:02:31 Jun 10, 2018"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 20:08:43 Jul 12, 2018">12</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930193553/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 20:08:43 Jul 12, 2018">2018</td>
		  <td class="f" nowrap="nowrap">2019</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20180712200843*/https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml" title="See a list of every capture for this URL">6 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 12 Jul 2018</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archiveteam);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/archiveteam" target="_new"><span class="wm-title">Archive Team</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  <img align=right src="http://archiveteam.org/images/e/e6/Archiveteam.jpg" width=200> Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded into a large amount of related projects for saving online and digital history.
<p>
History is littered with hundreds of conflicts over the future of a community, group, location or business that were "resolved" when one of the parties stepped ahead and destroyed what was there. With the original point of contention destroyed, the debates would fall to the wayside. Archive Team believes that by duplicated condemned data, the conversation and debate can continue, as well as the richness and insight gained by keeping the materials. Our projects have ranged in size from a single volunteer downloading the data to a small-but-critical site, to over 100 volunteers stepping forward to acquire terabytes of user-created data to save for future generations.
<p>
The main site for Archive Team is at <a href="http://www.archiveteam.org">archiveteam.org</a> and contains up to the date information on various projects, manifestos, plans and walkthroughs.
<p>
This collection contains the output of many Archive Team projects, both ongoing and completed. Thanks to the generous providing of disk space by the Internet Archive, multi-terabyte datasets can be made available, as well as in use by the <a href="http://archive.org/web/web.php">Wayback Machine</a>, providing a path back to lost websites and work. 
<p>
Our collection has grown to the point of having sub-collections for the type of data we acquire. If you are seeking to browse the contents of these collections, the Wayback Machine is the best first stop. Otherwise, you are free to dig into the stacks to see what you may find.
<p>
<b>The Archive Team Panic Downloads</b> are full pulldowns of currently extant websites, meant to serve as emergency backups for needed sites that are in danger of closing, or which will be missed dearly if suddenly lost due to hard drive crashes or server failures. 
<p>
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archivebot)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/archivebot" target="_new"><span class="wm-title">ArchiveBot: The Archive Team Crowdsourced Crawler</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  ArchiveBot is an IRC bot designed to automate the archival of smaller websites (e.g. up to a few hundred thousand URLs). You give it a URL to start at, and it grabs all content under that URL, records it in a WARC, and then uploads that WARC to ArchiveTeam servers for eventual injection into the Internet Archive (or other archive sites).
<p>
To use ArchiveBot, drop by #archivebot on EFNet. To interact with ArchiveBot, you issue commands by typing it into the channel. Note you will need channel operator permissions in order to issue archiving jobs. The dashboard shows the sites being downloaded currently.
<p>
There is a dashboard running for the archivebot process at <a href="http://www.archivebot.com">http://www.archivebot.com</a>.
<p>
ArchiveBot's source code can be found at <a href="https://github.com/ArchiveTeam/ArchiveBot">https://github.com/ArchiveTeam/ArchiveBot</a>.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10373?contentType=xml","2018-07-12",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Optimal use of taxanes in metastatic breast cancer (MBC).</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Breast Tumour Team. Optimal use of taxanes in metastatic breast cancer (MBC). Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 16 p.&amp;nbsp;(Clinical practice guideline; no. BR-001).&amp;nbsp; [42 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following taxanes regimens are recommend for women with:</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li><strong>Anthracycline-na&amp;iuml;ve, tumours do not overexpress human epidermal growth factor receptor (HER)2</strong>.
    <p>If single-agent chemotherapy is preferred, sequential anthracycline followed by taxane at the time of disease progression, or vice versa, are acceptable alternatives. A survival benefit has not been shown for starting with a taxane.</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>An every 3-week (q3w) regimen of docetaxel 100 mg/m<sup>2</sup> is recommended. </li>
        <li>The following weekly taxane regimens are reasonable options if reduced risk of toxicities is desired:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Docetaxel 35&amp;ndash;40 mg/m<sup>2</sup> weekly, x3 every 4 weeks (q4w) or weekly, x6 every 8 weeks (q8w) </li>
            <li>Paclitaxel 80&amp;ndash;90 mg/m<sup>2</sup> weekly </li>
        </ul>
        </li>
    </ul>
    <p>If combination chemotherapy is preferred, non-taxane/anthracycline and taxane/anthracycline regimens are acceptable alternatives. Taxane/anthracycline combinations are superior with respect to overall response and progression-free survival (PFS), but have not been shown to improve overall survival (OS). Additionally, an OS benefit for using a taxane/anthracycline combination over planned sequential single-agent anthracycline followed by single-agent taxane (before disease progression), or at the time of disease progression has not been shown.</p>
    <p>Regarding possible taxane/anthracycline regimens, doublet docetaxel or paclitaxel plus doxorubicin or epirubicin, and triplet docetaxel + doxorubicin + cyclophosphamide have been studied.</p>
    </li>
    <li><strong>Anthracycline pretreated/resistant, tumours do not overexpress HER2</strong>.
    <p>If single-agent chemotherapy is preferred, a taxane regimen is recommended. Single-agent taxanes appear to improve OS and response compared with non-taxane/non-anthracycline regimens.</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>An every 3-week regimen of docetaxel 100 mg/m<sup>2</sup> is recommended. </li>
        <li>The following weekly taxane regimens are reasonable options if reduced risk of toxicities is desired:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Docetaxel 35&amp;ndash;40 mg/m<sup>2</sup> weekly, x3 q4w or weekly, x6 q8w </li>
            <li>Paclitaxel 80&amp;ndash;90 mg/m<sup>2</sup> weekly </li>
        </ul>
        </li>
    </ul>
    <p>If combination chemotherapy is preferred, taxane/non-anthracycline regimens are recommended. Taxane/non-anthracycline regimens are superior with respect to OS and response compared with single-agent taxanes. Definitive survival data with taxane/non-anthracycline combinations compared with sequential single-agent taxane followed by single-agent non-taxane/non-anthracycline (at progression) is not available.</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>The following taxane/non-anthracycline regimens should be options:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Docetaxel 75 mg/m<sup>2</sup> day 1 + capecitabine 1,250 mg/m<sup>2</sup>, twice daily (b.i.d), days 1&amp;ndash;14, q3w </li>
            <li>Docetaxel 75 mg/m<sup>2</sup> day 1 + gemcitabine 1000 mg/m<sup>2</sup> days 1 &amp;amp; 8, q3w </li>
            <li>Paclitaxel 175 mg/m<sup>2</sup> day 1 + gemcitabine 1250 mg/m<sup>2</sup> days 1 &amp;amp; 8, q3w </li>
        </ul>
        </li>
    </ul>
    </li>
    <li><strong>Anthracycline-na&amp;iuml;ve or pretreated/resistant with HER2 over-expression</strong>.
    <p>A taxane/trastuzumab combination is recommended up front. The addition of trastuzumab to a taxane has been shown to improve OS and response. Although the addition of trastuzumab to anthracycline regimens has also been shown to improve OS and response, the incidence of cardiac failure is unacceptable. The addition of carboplatin to taxane/trastuzumab combinations has not yet been shown to improve OS or consistently increase response.</p>
    <p>The strongest evidence is for the following single-agent taxane regimens plus weekly trastuzumab:</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Docetaxel 100 mg/m<sup>2</sup> q3w </li>
        <li>Paclitaxel 175 mg/m<sup>2</sup> q3w </li>
    </ul>
    </li>
    <li><strong>Anthracycline-na&amp;iuml;ve or pretreated/resistant AND paclitaxel or docetaxel intolerance</strong>.
    <p>For patients with intolerance to paclitaxel or docetaxel caused by a severe infusion reaction or severe toxicity from previous administration of a taxane, including corticosteroid intolerance, the following single-agent nab-paclitaxel regimens should be options:</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Nab-paclitaxel 260&amp;ndash;300 mg/m<sup>2</sup> q3w </li>
        <li>Nab-paclitaxel 100&amp;ndash;150 mg/m<sup>2</sup> weekly, x3 q4w </li>
    </ul>
    </li>
</ol></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Metastatic breast cancer</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Management"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Oncology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To promote evidence-based consistency in practice, and hence, equitable access for women with metastatic breast cancer (MBC) to appropriate therapies</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Adults over the age of 18 years with metastatic breast cancer (MBC) who are anthracycline na&amp;iuml;ve or pretreated/resistant</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Single-agent taxane therapy: docetaxel or paclitaxel </li>
    <li>Non-taxane/anthracycline and taxane/anthracycline regimens </li>
    <li>Taxane/non-anthracycline regimens (e.g., docetaxel + capecitabine, docetaxel + gemcitabine, paclitaxel + gemcitabine) </li>
    <li>Taxane/trastuzumab combination therapy </li>
    <li>Single-agent nab-paclitaxel therapy </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Response rates (overall) </li>
    <li>Survival rates (overall, progression-free) </li>
    <li>Time to progression </li>
    <li>Mortality </li>
    <li>Quality of life </li>
    <li>Toxicity (hematologic and non-hematologic) </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>Research Questions</span></strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (patient or population, intervention, comparisons, outcomes).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Guideline Questions</span></strong></p>
<p>What taxanes regimens can be offered to the following types of women with metastatic breast cancer (MBC)?</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Anthracycline-na&amp;iuml;ve, tumours do not overexpress human epidermal growth factor receptor (HER)2. </li>
    <li>Anthracycline pre-treated/resistant, tumours do not overexpress HER2. </li>
    <li>Anthracycline-na&amp;iuml;ve or pretreated/resistant, tumours overexpress HER2. </li>
    <li>Anthracycline-na&amp;iuml;ve or pretreated/resistant AND paclitaxel or docetaxel intolerance. </li>
</ol>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Search Strategy</span></strong></p>
<p><strong>Original Search Strategy</strong></p>
<p>A systematic search for relevant clinical practice guidelines and peer-reviewed medical literature was conducted using prominent developers' websites and databases, MEDLINE, PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, CancerLit, Cochrane Database of Systematic Reviews, Physician Data Query, as well as conference proceedings from the American Society of Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium. Search terms included: Taxane* Exp., Taxanes Exp., metastatic breast cancer exp., metastases, breast tumour, breast tumor, Women exp., Anthracycline exp., Anthracyclines exp.</p>
<p><strong>Updated Search Strategy</strong></p>
<p>A systematic search for relevant clinical practice guidelines published since 2009 was conducted using prominent developers' websites, National Guideline Clearinghouse and the Standards and Guidelines Evidence (SAGE) database. MEDLINE, PubMed, and Cochrane Database of Systematic Reviews was used to identify peer-reviewed literature using similar search terms listed above, for the period 2009 to May 8, 2013.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Meta-Analysis"/>
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was originally developed in December 2007 using the ADAPTE process and some aspects of the Practice Guidelines Development Cycle. The Comprehensive Meta-analysis Package Version 2 was used for data pooling where deemed appropriate. Random effects models were used to obtain odds ratios (OR) or rate ratios. This guideline was revised in December 2009 and September 2013.</p>
<p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Breast Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Trust Web site&quot;>http://www.agreetrust.org</a>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulated the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the Guideline Utilization Resource Unit Handbook (see the &quot;Availability of Companion Documents&quot; field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was reviewed and endorsed by the Alberta Provincial Breast Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Optimal use of taxanes in metastatic breast cancer (MBC)</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Treatment-related toxicity, including peripheral neuropathy, febrile neutropenia, mucositis, nausea/vomiting, cardiac failure, hematologic toxicity, and toxic deaths</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services Web site. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Breast Tumour Team. Optimal use of taxanes in metastatic breast cancer (MBC). Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 16 p.&amp;nbsp;(Clinical practice guideline; no. BR-001).&amp;nbsp; [42 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2013 Sep"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="CancerControl Alberta - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>CancerControl Alberta</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Alberta Provincial Breast Tumour Team</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Members of the Alberta Provincial Breast Tumour Team include medical oncologists, radiation oncologists, surgical oncologists, nurses, pathologists, and pharmacists.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Participation of members of the Alberta Provincial Breast Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Breast Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Available from the <a href=&quot;http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-br001-opt-use-taxanes.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on August 12, 2014. The information was verified by the guideline developer on September 22, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 20:08:43 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:09:54 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 80.853 (3)
  esindex: 0.008
  captures_list: 98.196
  CDXLines.iter: 12.801 (3)
  PetaboxLoader3.datanode: 72.053 (4)
  exclusion.robots: 0.781
  exclusion.robots.policy: 0.762
  RedisCDXSource: 0.736
  PetaboxLoader3.resolve: 336.817
  load_resource: 382.141
-->